CD22: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CD22. The page also collects GeneMedi's different modalities and formats products for CD22 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD22 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
Predicted to enable CD4 receptor binding activity; protein phosphatase binding activity; and sialic acid binding activity. Involved in B cell activation; negative regulation of B cell receptor signaling pathway; and regulation of endocytosis. Located in early endosome and recycling endosome. [provided by Alliance of Genome Resources, Apr 2022]
| Target ID | GM-T37539 |
| Target Name | CD22 |
| Gene ID | 933 |
| Gene Official Name | CD22 |
| Gene Alias | SIGLEC-2, SIGLEC2 |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, INN Index, Immuno-oncology Target |
Pre-made CD22-specific INN-index biosimilar (antibody&conjugates)-Moxetumomab, inotuzumab ozogamicin, Inotuzumab, pinatuzumab vedotin, Epratuzumab, bectumomab, Pinatuzumab, Suciraslimab, moxetumomab pasudotox
Anti-CD22 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Pre-made anti-CD22 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CD22 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD22 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Cat No. | Antibody Name | Format | Classified by tag | Order |
| GM-Tg-hg-T37539-Ab | Anti-CD22 monoclonal antibody | mab | Biofunctional antibody, Therapeutics Target antibody |  |
Facebook
LinkedIn
Twitter
